Eylea Approved In EU For Visual Impairment Due To Macular Edema Secondary To CRVO

Home
Cataract
Cornea
Glaucoma
Refractive
Retina
Practice Management

Monday, September 2, 2013

Ocular Surgery News

The European Commission has approved Eylea (aflibercept, Regeneron Pharmaceuticals Inc.) for the treatment of visual impairment from macular edema secondary to central retinal vein occlusion, Regeneron announced.

Full Story

Aspirin usage increases the risk of bleeding in patients with proliferative retinopathy?
1. True
2. False
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Eylea Approved In EU For Visual Impairment Due To Macular Edema Secondary To CRVO

Comments

Quick Quiz

Aspirin usage increases the risk of bleeding in patients with proliferative retinopathy?

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

Write for Us

AdGlare RMR2